Bedtime Fibromyalgia Therapy TNX-102 SL Sees Faster-than-expected Trial Enrollment
Jul 07, 2020 07:00 am | Steve Bryson PhD
Enrollment in the RELIEF Phase 3 trial assessing TNX-102 SL (sublingual cyclobenzaprine) as a nighttime treatment for pain and disturbed sleep due to fibromyalgia has been faster than expected, according to Tonix Pharmaceuticals, therapy’s developer. The company now anticipates enrollment completion from July to September, and top-line results later this year instead of next year. The […]
The post Bedtime Fibromyalgia Therapy TNX-102 SL Sees Faster-than-expected Trial Enrollment appeared first on Fibromyalgia News Today. |
Enrollment in the RELIEF Phase 3 trial assessing TNX-102 SL (sublingual cyclobenzaprine) as a nighttime treatment for pain and disturbed sleep due to fibromyalgia has been faster than expected, according to Tonix Pharmaceuticals, therapy’s developer. The company now anticipates enrollment completion from July to September, and top-line results later this year instead of next year. The […]
